Laura Stoppel, PhD

Partner

Laura Stoppel is a Partner at RA Capital Management. Laura’s primary responsibilities are to work on both public and private investments and serve as a Board Director for Artiva Biotherapeutics, Nimbus Therapeutics, CellCentric Ltd., Verdiva Bio, Infinant Health, and Acumen Pharmaceuticals. Laura’s graduate research investigated synaptic translation in syndromic autism. Laura holds a Bachelor of Arts in Biology and Psychology from Harvard University and a PhD in Neuroscience from the Massachusetts Institute of Technology.